Known targets — ChEMBL curated mechanism
EGFRERBB2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9
The experimentally established mechanism targets of Cudc-101. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 14/20 | 1.00 |
| ▸ | HDAC4 known ✓ | P56524 | 14/20 | 1.00 |
| ▸ | HDAC1 known ✓ | Q13547 | 14/20 | 1.00 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 14/20 | 1.00 |
| ▸ | HDAC2 known ✓ | Q92769 | 14/20 | 1.00 |
| ▸ | HDAC10 known ✓ | Q969S8 | 14/20 | 1.00 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 14/20 | 1.00 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 14/20 | 1.00 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 14/20 | 1.00 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 14/20 | 1.00 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 14/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 8/20 | 1.00 |
| ▸ | EGFR known ✓ | P00533 | 8/20 | 1.00 |
| ▸ | KDR | P35968 | 7/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | BUB1 | O43683 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8212688 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4740600 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL641667 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Cudc-101 SCHEMBL29350202 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Cudc-101 SCHEMBL29379912 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL31424948 | 0.99 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8213005 | 0.99 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL643712 | 0.99 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL642322 | 0.97 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8205021 | 0.94 | ERBB2 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12529091-B2 | ATAC-array for prediction of disease-free survival in pancreatic cancer | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2026-01-20 | — | — | US | claimed |
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| US-12220464-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-02-11 | — | — | US | claimed |
| US-20230285498-A1 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE | 2023-09-14 | — | — | US | claimed |
| US-20200199538-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2020-06-25 | — | — | US | claimed |
| EP-3048874-B1 | HAPLOID EMBRYOGENESIS | STICHTING WAGENINGEN RES (NL) | 2019-08-07 | — | — | EP | claimed |
| EP-3350313-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | Agency For Science, Technology And Research (A*star) (SG) | 2018-07-25 | — | — | EP | claimed |
| WO-2017048193-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2017-03-23 | — | — | WO | claimed |
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2016-12-01 | — | — | US | claimed |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2015-02-19 | — | — | US | claimed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | claimed |
| US-12630501-B2 | Anti-fibrotic compounds and use thereof | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2026-05-19 | — | — | US | disclosed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| US-20250367145-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KIDNEY DISEASES | UNIVERSITÄTSMEDIZIN GREIFSWALD (DE) | 2025-12-04 | — | — | US | disclosed |
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | disclosed |
| US-20080139590-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008033749-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033749-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | HDAC3 942/4885HDAC4 487/4885HDAC1 713/4885 |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | HDAC3 1207/4885HDAC4 2349/4885HDAC1 517/4885 |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | HDAC3 942/4885HDAC4 487/4885HDAC1 713/4885 |
| US-12630501-B2 | Anti-fibrotic compounds and use thereof | SIRT1, SIRT2, SIRT3 | HDAC3 5/4885HDAC4 27/4885HDAC1 10/4885 |
| US-20080139590-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC6 | HDAC3 15/4885HDAC4 5/4885HDAC1 2/4885 |
| US-12220464-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | HDAC3 953/4885HDAC4 973/4885HDAC1 695/4885 |
| US-20250367145-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KIDNEY DISEASES | REN, SLC10A1, GLS | HDAC3 573/4885HDAC4 1252/4885HDAC1 1068/4885 |
| US-12529091-B2 | ATAC-array for prediction of disease-free survival in pancreatic cancer | ABCC1, EPCAM, ABCF2 | HDAC3 912/4885HDAC4 629/4885HDAC1 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.